News >

De-Escalation Possible in Curative Setting for HER2+ Breast Cancer

Kristi Rosa
Published: Tuesday, Dec 18, 2018

Ciara O'Sullivan, MB, BCh

Ciara O'Sullivan, MB, BCh

Treatment de-escalation for patients with HER2-positive breast cancer is feasible and imperative, explained Ciara O’Sullivan, MB, BCh, and as the field continues to evolve, more efforts will be directed at tailoring HER2-directed therapies more effectively.

Studies have assessed and confirmed the benefit of de-escalating therapy for patients with early-stage HER2-positive breast cancer. For example, 7-year follow-up data from the APT trial showed that patients with HER2-positive lesions and negative lymph nodes may not necessarily need additional HER2-targeted therapy. Results from the analysis demonstrated a 93.3% disease-free survival rate with the use of adjuvant paclitaxel and trastuzumab (Herceptin) for 12 weeks, followed by 39 weeks of weekly trastuzumab.1

The NSABP B-52 trial evaluated the regimen of docetaxel, trastuzumab, and pertuzumab (Perjeta) alone or in combination with endocrine therapy in patients with hormone receptor–positive, HER2-positive breast cancer. These patients went on to have surgery, with a primary endpoint of pathologic complete response (pCR).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication